N/A N=22 Peer Support for Exercise in Older Veterans With Psychotic Disorders
Psychotic Disorder
Primary: Intervention Engagement — 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 iTEST: Introspective Accuracy as a Novel Target for Functioning in Psychotic Disorders
Schizophrenia · Schizo Affective Disorder · Psychotic Disorders
Primary: Trained Introspective Accuracy — 3.70; -0.77 score on a scale — p=<0.001
Phase 2 N=216 A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)
Schizophrenia
Primary: Mean Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) at Week 4 — -13.3; -17.0; -12.7 Units on a scale — p=0.8590
Phase 2 N=63 A Multicenter Study of NAP (AL-108) in Schizophrenia
Schizophrenia
Primary: Change in MATRICS Consensus Cognitive Battery Composite Score Change — 1.3; 2.3; -0.2 units on a scale
Phase 2 N=28 Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Primary Clinical Outcome PANSS Total Score (PANSSt) — 65.4; 55.6; 67.1; 49.8 score on a scale — p=0.28
N/A N=2,018 Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With ASD
Autistic Disorder · Autism · ASD
Primary: Improvement of Language as Measured by Autism Therapy Evaluation Checklist (ATEC) and Mental Synthesis Evaluation Checklist (MSEC). — 8.49; 4.87; 5.03; 3.53 units on a…
N/A N=3,083 High Impact E-cigarette Advertisement Features
Vaping Behavior
Primary: Intentions of Using the E-cigarette — 5.27; 5.56; 5.52; 5.70 score on a scale
N/A N=3,389 BRADYCARE: Advanced Bradycardia Device Feature Utilization and Clinical Outcomes
Pacemaker
Primary: Complication Rate at 1-year Post-implant — 1.12 percentage of enrolled subjects
Phase 2 N=63 Treatment Study for Cognitive Deficits in Schizophrenia
Schizophrenia
Primary: Composite MATRICS Consensus Cognitive Battery Score — 27.9; 31.3; 32.5 composite score — p=0.21
Phase 3 N=252 A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)
Schizophrenia · Schizophrenia; Psychosis
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 — -21.2; -11.6 score on a scale — p=<0.0001
Phase 3 N=256 A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)
Schizophrenia · Schizophrenia; Psychosis
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 — -20.6; -12.2 Score on a scale
Phase 3 N=403 A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12 — 77.18; 58.46; 63.33; -26.29 unit on a scale
Phase 2 N=88 A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder
Schizophrenia · Schizophrenia-related Psychotic Disorder
Primary: Change From Baseline To End Of Treatment (Day 43) In Positive And Negative Syndrome Scale (PANSS) Total Score — 79.3; 80.6; 68.1; 71.9 score on a scale — p=0.1332
Phase 2 N=27 Effects of Oxytocin Nasal Spray on Social Affiliation
Schizophrenia
Primary: Social Affiliation Measured by Social Affiliative Role Play — 4.026; 4.111; 4.079; 4.194 units on a scale — p=0.758
Phase 2 N=12 Effects of Galantamine on Cognition
Schizophrenia
Primary: RVIP Target Hit and False Alarm (Number of Responses) — 23.4; 22.8; 19.7; 14.88 Number of responses — p=0.898